Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the EORTC 62092-22092 STRASS trial.

Haas, Rick; Stelmes, Jean-Jacques; Zaffaroni, Facundo; Sauvé, Nicolas; Clementel, Enrico; Bar-Deroma, Raquel; Le Péchoux, Cécile; Litière, Saskia; Marreaud, Sandrine; Alyamani, Najlaa; Andratschke, Nicolaus H J; Sangalli, Claudia; Chung, Peter W; Miah, Aisha; Hurkmans, Coen; Gronchi, Alessandro; Bovée, Judith V M G; Gelderblom, Hans; Kasper, Bernd; Weber, Damien Charles; ... (2022). Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the EORTC 62092-22092 STRASS trial. Cancer, 128(14), pp. 2796-2805. Wiley 10.1002/cncr.34239

Text Cancer_-_2022_-_Haas_-_Critical_impact_of_radiotherapy_protocol_compliance_and_quality_in_the_treatment_of_retroperitoneal.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (521kB) | Request a copy

BACKGROUND

The European Organization for Research and Treatment of Cancer 22092-62092 STRASS trial failed to demonstrate the superiority of neoadjuvant radiotherapy (RT) over surgery alone in patients with retroperitoneal sarcoma. Therefore, an RT quality-assurance program was added to the study protocol to detect and correct RT deviations. The authors report results from the trial RT quality-assurance program and its potential effect on patient outcomes.

METHODS

To evaluate the effect of RT compliance on survival outcomes, a composite end point was created. It combined the information related to planning target volume coverage, target delineation, total dose received, and overall treatment time into 2 groups: non-RT-compliant (NRC) for patients who had unacceptable deviation(s) in any of the previous categories and RT-compliant (RC) otherwise. Abdominal recurrence-free survival (ARFS) and overall survival were compared between the 2 groups using a Cox proportional hazard model adjusted for known prognostic factors.

RESULTS

Thirty-six of 125 patients (28.8%) were classified as NRC, and the remaining 89 patients (71.2%) were classified as RC. The 3-year ARFS rate was 66.8% (95% confidence interval [CI], 55.8%-75.7%) and 49.8% (95% CI, 32.7%-64.8%) for the RC and NRC groups, respectively (adjusted hazard ratio, 2.32; 95% CI, 1.25-4.32; P = .008). Local recurrence after macroscopic complete resection occurred in 13 of 89 patients (14.6%) versus 2 of 36 patients (5.6%) in the RC and NRC groups, respectively.

CONCLUSIONS

The current analysis suggests a significant benefit in terms of ARFS in favor of the RC group. This association did not translate into less local relapses after complete resection in the RC group. Multidisciplinary collaboration and review of cases are critical to avoid geographic misses, especially for rare tumors like retroperitoneal sarcoma.

Interest & Impact

Downloads

1 since deposited on 27 Oct 2022
1 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item